Mutual of America Capital Management LLC Trims Stock Holdings in Laboratory Co. of America Holdings (NYSE:LH)

Mutual of America Capital Management LLC decreased its stake in Laboratory Co. of America Holdings (NYSE:LH) by 8.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 13,474 shares of the medical research company’s stock after selling 1,262 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Laboratory Co. of America were worth $3,063,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Eagle Bay Advisors LLC bought a new position in shares of Laboratory Co. of America in the second quarter worth about $29,000. Mendota Financial Group LLC bought a new position in Laboratory Co. of America during the fourth quarter valued at approximately $29,000. Provence Wealth Management Group bought a new position in Laboratory Co. of America during the third quarter valued at approximately $29,000. Tradewinds Capital Management LLC bought a new position in Laboratory Co. of America during the third quarter valued at approximately $34,000. Finally, Exchange Traded Concepts LLC bought a new position in Laboratory Co. of America during the third quarter valued at approximately $37,000. Hedge funds and other institutional investors own 95.94% of the company’s stock.

Insider Buying and Selling at Laboratory Co. of America

In other Laboratory Co. of America news, EVP Der Vaart Sandra D. Van sold 259 shares of the stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $222.06, for a total transaction of $57,513.54. Following the sale, the executive vice president now owns 7,637 shares of the company’s stock, valued at approximately $1,695,872.22. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Laboratory Co. of America news, EVP Der Vaart Sandra D. Van sold 259 shares of the stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $222.06, for a total transaction of $57,513.54. Following the sale, the executive vice president now owns 7,637 shares of the company’s stock, valued at approximately $1,695,872.22. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Der Vaart Sandra D. Van sold 237 shares of the business’s stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $226.45, for a total value of $53,668.65. Following the transaction, the executive vice president now owns 7,637 shares in the company, valued at $1,729,398.65. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 54,305 shares of company stock valued at $11,761,059. 0.85% of the stock is currently owned by corporate insiders.

Laboratory Co. of America Trading Down 0.3 %

LH opened at $199.44 on Friday. The stock’s fifty day moving average is $214.16 and its two-hundred day moving average is $214.58. The company has a market capitalization of $16.78 billion, a P/E ratio of 42.71, a PEG ratio of 1.52 and a beta of 1.01. Laboratory Co. of America Holdings has a 52 week low of $174.20 and a 52 week high of $234.09. The company has a quick ratio of 1.02, a current ratio of 1.17 and a debt-to-equity ratio of 0.52.

Laboratory Co. of America (NYSE:LH) last released its quarterly earnings data on Thursday, February 15th. The medical research company reported $3.30 EPS for the quarter, topping the consensus estimate of $3.29 by $0.01. The company had revenue of $3.03 billion for the quarter, compared to the consensus estimate of $3.02 billion. Laboratory Co. of America had a return on equity of 13.99% and a net margin of 3.24%. Laboratory Co. of America’s quarterly revenue was down 17.5% on a year-over-year basis. During the same period last year, the business posted $4.14 EPS. Analysts forecast that Laboratory Co. of America Holdings will post 14.84 earnings per share for the current year.

Laboratory Co. of America Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, June 12th. Shareholders of record on Tuesday, May 28th will be given a dividend of $0.72 per share. The ex-dividend date is Friday, May 24th. This represents a $2.88 annualized dividend and a yield of 1.44%. Laboratory Co. of America’s dividend payout ratio (DPR) is presently 61.67%.

Analysts Set New Price Targets

A number of equities analysts recently commented on LH shares. Leerink Partnrs reissued an “outperform” rating on shares of Laboratory Co. of America in a research note on Monday, February 26th. SVB Leerink assumed coverage on Laboratory Co. of America in a research note on Monday, February 26th. They issued an “outperform” rating and a $260.00 price objective for the company. TheStreet lowered Laboratory Co. of America from a “b-” rating to a “c+” rating in a research note on Thursday, February 15th. Evercore ISI assumed coverage on Laboratory Co. of America in a research note on Friday, February 9th. They issued an “in-line” rating and a $240.00 price objective for the company. Finally, Argus raised Laboratory Co. of America from a “hold” rating to a “buy” rating and set a $250.00 price objective for the company in a research note on Monday, March 25th. Four equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $243.50.

About Laboratory Co. of America

Laboratory Corporation of America Holdings operates as a life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Biopharma Laboratory Services (BLS).